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Background: Germline mutations in BRCA1 and BRCA2 (BRCA) are the main cause of Hereditary Breast and Ovarian Cancer 
syndrome (HBOC). Methods: In this study we evaluated the mutational profile and prevalence of BRCA mutations among probands 
fulfilling the NCCN HBOC testing criteria. We characterized the clinical profile of these individuals and explored the performance of 
international testing criteria. Results: A pathogenic mutation was detected in 19.1% of 418 probands, including seven novel 
frameshift mutations. Variants of uncertain significance were found in 5.7% of individuals. We evaluated 50 testing criteria and 
mutation probability algorithms. There was a significant odds-ratio (OR) for mutation prediction (p ≤ 0.05) for 25 criteria; 14 of these 
had p ≤ 0.001. Using a cutoff point of four criteria, the sensitivity is 83.8%, and the specificity is 53.5% for being a carr ier. Mutation 
prevalence for each criterion ranged from 22.1% to 55.6%, and criteria with the highest ORs were those related to triple-negative 
breast cancer or ovarian cancer. Conclusions: This is the largest study of comprehensive BRCA testing among Brazilians to date, 
and the first to analyze clinical criteria for genetic testing. Several criteria that are not included in the NCCN achieved a higher 
predictive value. Identification of the most informative criteria for each population will assist in the development of a rational 
approach to genetic testing, and will enable the prioritization of high-risk individuals as a first step towards offering testing in low-
income countries. Palavras-chaves: BRCA1, BRCA2, HBOC  
 
